Video

Dr. Karlan Describes AMG 386 Side Effects

Author(s):

Beth Y. Karlan MD

Dr. Karlan Describes AMG 386 Side Effects Found in the Phase II Ovarian Cancer Trial

Beth Y. Karlan MD, a Director at Cedars-Sinai Women's Cancer Research Institute Describes AMG 386 Side Effects Found in the Phase II Ovarian Cancer Trial

Related Videos
Andrew Ip, MD
Mansi R. Shah, MD
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
Sagar D. Sardesai, MBBS
Ashkan Emadi, MD, PhD
Matthew J. Baker, PhD
Manmeet Ahluwalia, MD, MBA, FASCO
John Mascarenhas, MD
Related Content
Ovarian Cancer
December 20th 2024

Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

stock.adobe.com
December 16th 2024

Dostarlimab Plus Chemo Earns Positive CHMP Opinion for Expanded Indication in Advanced Endometrial Cancer

R. Wendel Naumann, MD
October 26th 2023

Naumann Discusses Notable Research Efforts in Endometrial Cancer

Ovarian Cancer_Dr Microbe - stock.adobe.com
December 10th 2024

Luveltamab Tazevibulin Produces Responses in Platinum-Resistant Ovarian Cancer

Stephanie Gaillard, MD, PhD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
December 10th 2024

New ADCs Join NCCN Guidelines for Gynecologic Cancers Representing Step Forward